IP Library › Granted Patent US 12,530,770
Granted Patent B2
US 12,530,770 · App. 18/461,686 · Granted Jan 20, 2026

Deep-learning-based hepatic fat assessment

Inventors: Gourav Modanwal (Cleveland, OH); Sadeer Al-Kindi (Cleveland, OH); Jonathan Walker (Cleveland, OH); Rohan Dhamdhere (Atlanta, GA); Sanjay Rajagopalan (Cleveland, OH); Anant Madabhushi (Decatur, GA)
Assignees: Case Western Reserve University; Emory University; University Hospitals Cleveland Medical Center
G06T7/0012A61B5/0033A61B5/0073A61B5/416A61B5/4244G06T7/11G06T2207/10081G06T2207/20081G06T2207/20084G06T2207/30056
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,530,770
App. No.
18/461,686
Granted
Jan 20, 2026
Kind
B2
Abstract

The present disclosure relates to a method. The method includes accessing automatically segmented liver data and automatically segmented spleen data from a patient. The automatically segmented liver data is used to determine a liver attenuation and the automatically segmented spleen data is used to determine a spleen attenuation. A liver-to-spleen attenuation ratio is determined from the liver attenuation and the spleen attenuation. A hepatic steatosis determination is made from the liver-to-spleen attenuation ratio.

Claims (47)

1 . A method, comprising:

accessing automatically segmented liver data and automatically segmented spleen data from a patient, wherein the automatically segmented liver data comprises a region of interest from a digitized image of a liver and the automatically segmented spleen data comprises a region of interest from a digitized image of a spleen;

utilizing the automatically segmented liver data to determine a liver attenuation;

utilizing the automatically segmented spleen data to determine a spleen attenuation;

determining a liver-to-spleen attenuation ratio from the liver attenuation and the spleen attenuation; and

making a hepatic steatosis determination from the liver-to-spleen attenuation ratio.

2 . The method of claim 1 , wherein the spleen attenuation and the liver attenuation are determined by a slice-based estimation method configured to identify a slice of the digitized image of the liver with a maximum liver area or a slice of the digitized image of the spleen with a maximum spleen area and to obtain a mean attenuation across an entire liver and an entire spleen within the slice.

3 . The method of claim 1 , wherein the spleen attenuation and the liver attenuation are determined by a volume-based estimation configured to obtain a mean attenuation across an entire liver and an entire spleen over a three-dimensional image volume.

4 . The method of claim 1 , wherein the liver-to-spleen attenuation ratio is obtained by:

measuring a first mean value of Hounsfield units over an entirety of a segmented liver identified by the automatically segmented liver data;

measuring a second mean value of Hounsfield units over an entirety of a segmented spleen identified by the automatically segmented spleen data; and

dividing the first mean value of Hounsfield units by the second mean value of Hounsfield units to obtain the liver-to-spleen attenuation ratio.

5 . The method of claim 1 , further comprising:

accessing one or more digitized images comprising a liver and a spleen;

operating one or more deep learning models on the one or more digitized images to segment the liver and generate the automatically segmented liver data;

operating the one or more deep learning models on the one or more digitized images to segment the spleen and generate the automatically segmented spleen data; and

storing the automatically segmented liver data and the automatically segmented spleen data in an electronic memory.

6 . The method of claim 5 , wherein the one or more digitized images comprise low-dose non-contrast computed tomography (CT) images.

7 . The method of claim 5 , wherein the one or more deep learning models comprise a 3D residual-UNet architecture from nnUnet framework.

8 . The method of claim 5 , further comprising:

training the one or more deep learning models on a plurality of computed tomography (CT) images.

9 . The method of claim 8 , wherein one or more of the plurality of CT images used in training do not include an entire liver.

10 . The method of claim 1 , further comprising:

determining a risk assessment metric based on the hepatic steatosis determination, wherein the risk assessment metric corresponds to a severity of COVID symptoms that the patient is expected to experience due to a COVID infection; and

assigning a care level to the patient based on the risk assessment metric.

11 . A non-transitory computer-readable medium storing computer-executable instructions that, when executed, cause a processor to perform operations, comprising:

operating one or more deep learning models on one or more computed tomography (CT) images comprising a liver and a spleen, wherein the one or more deep learning models are configured to segment the liver and generate automatically segmented liver data and to segment the spleen and generate automatically segmented spleen data;

measuring a liver attenuation from the automatically segmented liver data;

measuring a spleen attenuation from the automatically segmented spleen data;

determining a liver-to-spleen attenuation ratio from the liver attenuation and the spleen attenuation; and

generating a hepatic steatosis determination from the liver-to-spleen attenuation ratio.

12 . The non-transitory computer-readable medium of claim 11 , wherein the one or more deep learning models comprise a single deep learning model.

13 . The non-transitory computer-readable medium of claim 11 , wherein the operations further comprise:

determining one or more risk assessment metrics based on the hepatic steatosis determination.

14 . The non-transitory computer-readable medium of claim 13 , wherein the one or more risk assessment metrics comprise one or more of a COVID severity metric and a cardiovascular disease metric.

15 . The non-transitory computer-readable medium of claim 11 , wherein the one or more CT images comprise low-dose non-contrast computed tomography images.

16 . The non-transitory computer-readable medium of claim 11 , wherein the spleen attenuation and the liver attenuation are determined by a slice-based estimation method configured to identify a slice of a digitized image with a maximum area and obtain a mean attenuation across an entire liver and an entire spleen within the slice.

17 . The non-transitory computer-readable medium of claim 11 , wherein the spleen attenuation and the liver attenuation are determined by a volume-based estimation configured to obtain a mean attenuation across an entire liver and an entire spleen over a three-dimensional image volume.

18 . An apparatus, comprising:

one or more deep learning models configured to operate upon one or more digitized images that include a liver and a spleen to generate automatically segmented liver data and automatically segmented spleen data;

an attenuation calculation tool configured to utilize the automatically segmented liver data to measure a liver attenuation, to utilize the automatically segmented spleen data to measure a spleen attenuation, and to determine a liver-to-spleen attenuation ratio from the liver attenuation and the spleen attenuation; and

a hepatic steatosis calculation tool configured to generate a hepatic steatosis (HS) determination by comparing the liver-to-spleen attenuation ratio to an hepatic steatosis threshold.

19 . The apparatus of claim 18 , wherein the one or more deep learning models are configured to generate one or more binary masks that include the automatically segmented liver data identifying a segmented liver and that include the automatically segmented spleen data identifying a segmented spleen.

20 . The apparatus of claim 19 , wherein the liver-to-spleen attenuation ratio is obtained by:

measuring the liver attenuation as a first mean value of Hounsfield units over an entirety of the segmented liver;

measuring the spleen attenuation as a second mean value of Hounsfield units over an entirety of the segmented spleen; and

dividing the first mean value of Hounsfield units by the second mean value of Hounsfield units to obtain the liver-to-spleen attenuation ratio.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2025
From: MODANWAL, GOURAV; DHAMDHERE, ROHAN; MADABHUSHI, ANANT
To: CASE WESTERN RESERVE UNIVERSITY; EMORY UNIVERSITY
Reel/Frame 072698/0969 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 28, 2025
From: AL-KINDI, SADEER; WALKER, JONATHAN; RAJAGOPALAN, SANJAY
To: CASE WESTERN RESERVE UNIVERSITY; UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER
Reel/Frame 072699/0163 →
LICENSE Recorded Aug 8, 2024
From: CASE WESTERN RESERVE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH
Reel/Frame 068219/0085 →
Continuity (2)
Provisional Application 63508310 · Jun 15, 2023
Related Publication 20240420320A1 · Dec 19, 2024
References Cited (14)
US 11227683B2 · Morard · 2022 [cited by examiner]
US 12315147B2 · Rexhepaj · 2025 [cited by examiner]
US 20180260957A1 · Yang · 2018 [cited by examiner]
US 20250272837A1 · Rexhepaj · 2025 [cited by examiner]
Huo, Yuankai, et al. “Fully automatic liver attenuation estimation combing CNN segmentation and morphological operations.” Medical physics 46(8), pp. 3508-3519 (Year: 2019). [cited by examiner]
Jang, Weon, and Ji Soo Song. “Non-invasive imaging methods to evaluate non-alcoholic fatty liver disease with fat quantification: a review.” Diagnostics 13(11), 1852 (Year: 2023). [cited by examiner]
Jeon, Sun Kyung, et al. “Automated hepatic steatosis assessment on dual-energy CT-derived virtual non-contrast images through fully-automated 3D organ segmentation.” La radiologia medica 129(7), pp. 967-976 (Year: 2024). [cited by examiner]
Johnston, R. J., et al. “Diagnosis of fatty infiltration of the liver on contrast enhanced CT: limitations of liver-minus-spleen attenuation difference measurements.” Abdominal imaging 23(4), pp. 409-415. (Year: 1998). [cited by examiner]
Kim, Jong Man, et al. “Predicting hepatic steatosis in living liver donors via noninvasive methods.” Medicine 95(7), pp. 1-7 (Year: 2016). [cited by examiner]
Kodama, Yoshihisa, et al. “Comparison of CT methods for determining the fat content of the liver.” American Journal of Roentgenology 188(5), pp. 1307-1312 (Year: 2007). [cited by examiner]
Lăpădat, A. M., et al. “Non-invasive imaging techniques in assessing non-alcoholic fatty liver disease: a current status of available methods.” Journal of medicine and life 10(1), pp. 19-26 (Year: 2017). [cited by examiner]
Rogier, Julien, et al. “Noninvasive assessment of macrovesicular liver steatosis in cadaveric donors based on computed tomography liver-to-spleen attenuation ratio.” Liver Transplantation 21(5), pp. 690-695 (Year: 2015). [cited by examiner]
Yoo, Jeongin, et al. “Utilizing fully-automated 3D organ segmentation for hepatic steatosis assessment with CT attenuation-based parameters.” European Radiology 34(9), pp. 6205-6213 (Year: 2024). [cited by examiner]
Zhang, Zhongyi, et al. “Fully Automated Deep Learning-enabled Detection for Hepatic Steatosis on Computed Tomography: A Multicenter International Validation Study.” arXiv preprint arXiv:2210.15149 (Year: 2022). [cited by examiner]